PB0100 - Thromboelastography (TEG) as an Outcome Predictor Marker of Covid-19 Patients in Malang Indonesia

Sunday, July 10, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Presenting Author(s)

Shinta Oktya Wardhani, PhD

Hematology and Medical Oncology
Universitas Brawijaya
Malang, Jawa Timur, Indonesia

Co-Author(s)

DH

Djoko H. Hermanto

Hematology and Medical Oncologist
Universitas Brawijaya
Malang, Jawa Timur, Indonesia
Siti Fatonah, MD

Medical Staf
Universitas Brawijaya/ dr Saiful Anwar General Hospital
Kota Malang, Jawa Timur, Indonesia
JF

Jonny K. Fajar

Internist
Universitas Brawijaya
Malang, Jawa Timur, Indonesia

Background: Evidence suggested that severe COVID-19, a condition associated with a high mortality rate, is aggravated by significant coagulopathy which manifests in the form of microthrombosis and venous thromboembolism(VTE). Therefore,easy and accurate markers are required to assess coagulopathic changes in Covid-19 patients as the basis for providing prophylactic anticoagulant therapy to prevent thrombosis.

Aims: Our study aimed to assess the potential predictor of Thromboelastography(TEG) to estimate the outcome of COVID-19 patients

Methods: A cross-sectional study approved by local the ethical committee, was conducted in Dr.Saiful Anwar Hospital. The potential interest data, retrieved from medical records, were extracted, ie:TEG, thrombocytes levels, the severity of COVID-19 patients, and themortality rate of COVID-19 patients. The diagnosis of COVID-19 was confirmed by reverse-transcription polymerase chain reaction(RT-PCR). The comparison between TEG and the risk of mortality among patients with COVID-19 was analyzed using multiple logistic regression. We applied Graphad Prism version 9 (Graphad, Sandiego,CA) to analyze the data

Results: A total of 63 patients, employed from medical records, were included in this study, in which the survival rate was 65% and 22 patients died. Our study population between groups was age and sex-matched(Tab1). Our current findings revealed that hypercoagulation TEG was associated with 12,67-fold increase risk of mortality compared to those normocoagulation or hypocoagulation TEG(Fig1). Moreover, we also found that, among all TEG parameters, Lys30 was the only parameter having the greatest pivotal impact to govern the mortality of COVID-19 patients. We found that higher levels of Lys30 (MD95%CI: 26.90[13.34-40.47]) was associated with increase risk of mortality among patients with COVID-19(Fig1). On the other hand, our study also confirmed that the levels of CI and MA were observed higher in mortality group than in survival group

Conclusion(s): Our current study indicated that hypercoagulation TEG, excess fibrinolysis (Lys30), CI and MA increased the risk of mortality among patients with COVID-19